LONG MINI FUTURE - ELI LILLY & CO | Real-time Bid/Ask 10:30:16 10/05/2024 BST | ||
| 2.37 CHF / 2.39 CHF | -0.83% |
|
| Current month | -0.83% | ||
| 1 month | -2.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/05/24 | 2.4 | +1.27% | 0 |
| 07/05/24 | 2.37 | +7.73% | 0 |
| 06/05/24 | 2.2 | +10.00% | 0 |
| 03/05/24 | 2 | -14.89% | 0 |
| 02/05/24 | 2.35 | -2.89% | 0 |
Delayed Quote Swiss Exchange
Last update May 08, 2024 at 04:20 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| MLLAFV | |
| ISIN | CH1290585335 |
| Date issued | 31/08/2023 |
| Strike | 511.4 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.62 CHF |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | CHF |
Technical Indicators
| Highest since issue | 2.56 CHF |
|---|---|
| Lowest since issue | 0.34 CHF |
| Spread | 0.02 CHF |
| Spread % | 0.84% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
771.6
USD
Average target price
850.4
USD
Spread / Average Target
+10.22%
- Stock Market
- Certificates
- MLLAFV Certificat
